BAVARIAN NORDIC WKN: 917165 ISIN: DK0015998017 Kürzel: 0DPB Forum: Aktien Thema: Hauptdiskussion

Das wird Biontech 2.0.......die Chance lassen sich nur wenige entgehen👍

Auf zur 80€

Habe heute noch brav eingekauft, 😀😄

Wir 2 war die einzige hahaha Schön!

Ich ärger euch Flachköpper doch nurn bisschen, atmet mal locker durch die Hose bakd gibts wieder Nadeln und Masken.

About Bavarian Nordic Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Jupp

Davon hatten wir am Wochenende schon hingewiesen 🥳👍 Morgen wird ein toller Tag 👍🥳

A number of contracts of varying size have been signed Deliveries to start immediately aiming to ensure a rapid response to the current monkeypox outbreak Company upgrades its financial guidance for 2022 COPENHAGEN, Denmark, May 30, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the signing of a number of supply contracts with undisclosed countries for the Company’s smallpox vaccine with the aim to ensure sufficient supply to meet the requirements for vaccinating individuals at risk for monkeypox in the short to medium term. The vaccine is approved for use against monkeypox by the U.S. Food and Drug Administration and Health Canada as the only vaccine having obtained regulatory approval for this indication in any territory. While the terms of the agreements remain undisclosed, the sum of these orders will positively impact the Company’s financial guidance for 2022 as explained below. Bavarian Nordic is currently in dialogue with additional countries concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness. In this unprecedented situation, the Company is making every possible effort to ensure sufficient availability of vaccines to meet the current demand. Paul Chaplin, President and CEO of Bavarian Nordic said: “The current monkeypox outbreak continues to call for a swift and coordinated response from health authorities, and we are pleased to assist more countries with supply of vaccines while we continue our dialogues with other governments to make vaccines available as fast as possible to mitigate the situation.” As a consequence of these orders, Bavarian Nordic raises its expectations for the financial results for 2022 with revenue now expected to be between DKK 1,400 and 1,600 million (previously between DKK 1,300 and 1,500 million), EBITDA expectations raised to a loss between DKK 900 and 1,100 million (previously a loss between DKK 1,000 and 1,200 million) and cash and cash equivalents at year-end now between DKK 1,200 and 1,300 million (previously between DKK 1,100 and 1,200 million). The guidance reflects the significant investments in research and development being made in 2022 to advance the Company’s two lead product candidates: a vaccine against respiratory syncytial virus (RSV) and a booster vaccine against COVID-19 into Phase 3 clinical trials. About the smallpox/monkeypox vaccine MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. The vaccine was approved by the European Commission in 2013 for immunization against smallpox in adults aged 18 years and older and has subsequently gained regulatory approvals in Canada and the U.S. where the approval has been extended to include the monkeypox indication as the only vaccine having obtained this to-date. Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, the vaccine has been supplied in response to sporadic cases of monkeypox.

Geht gar nicht mehr auf Openinsider ein. Das ärgert den am meisten. 😂😂

Bavarian Nordic Enters Additional Vaccine Contracts with Governments in Response to Monkeypox Outbreak

Du sollst doch nicht dein Eigenbild auf andere projezieren.

Du bist ja so toll, das war meine letzte Antwort an dich. Geh raus und auch dir Freunde. Du hast definitiv Defizite in deinem Leben.

Ach Maxi die Laier zieht nicht mehr. Leg dich ins Bettchen Mama bringt den Kakao 🥱

Und genau das meine ich. Und dein Nachbar kennt jemand der wen kennt der die Zahlen aber nicht richtiger lesen kann.....kenne ich alles